Unger Holger W, Aho Celestine, Ome-Kaius Maria, Wangnapi Regina A, Umbers Alexandra J, Jack Wanda, Lafana Alice, Michael Audrey, Hanieh Sarah, Siba Peter, Mueller Ivo, Greenhill Andrew R, Rogerson Stephen J
Department of Medicine (Royal Melbourne Hospital), The University of Melbourne, Parkville, Australia Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
J Clin Microbiol. 2015 Apr;53(4):1317-23. doi: 10.1128/JCM.03570-14. Epub 2015 Feb 11.
Sulfadoxine-pyrimethamine (SP) plus azithromycin (AZ) (SPAZ) has the potential for intermittent preventive treatment of malaria in pregnancy (IPTp), but its use could increase circulation of antibiotic-resistant bacteria associated with severe pediatric infections. We evaluated the effect of monthly SPAZ-IPTp compared to a single course of SP plus chloroquine (SPCQ) on maternal nasopharyngeal carriage and antibiotic susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus at delivery among 854 women participating in a randomized controlled trial in Papua New Guinea. Serotyping was performed, and antibiotic susceptibility was evaluated by disk diffusion and Etest. Potential risk factors for carriage were examined. Nasopharyngeal carriage at delivery of S. pneumoniae (SPAZ, 7.2% [30/418], versus SPCQ, 19.3% [84/436]; P<0.001) and H. influenzae (2.9% [12/418] versus 6.0% [26/436], P=0.028), but not S. aureus, was significantly reduced among women who had received SPAZ-IPTp. The number of macrolide-resistant pneumococcal isolates was small but increased in the SPAZ group (13.3% [4/30], versus SPCQ, 2.2% [2/91]; P=0.033). The proportions of isolates with serotypes covered by the 13-valent pneumococcal conjugate vaccine were similar (SPAZ, 10.3% [3/29], versus SPCQ, 17.6% [16/91]; P=0.352). Although macrolide-resistant isolates were rare, they were more commonly detected in women who had received SPAZ-IPTp, despite the significant reduction of maternal carriage of S. pneumoniae and H. influenzae observed in this group. Future studies on SPAZ-IPTp should evaluate carriage and persistence of macrolide-resistant S. pneumoniae and other pathogenic bacteria in both mothers and infants and assess the clinical significance of their circulation.
周效磺胺-乙胺嘧啶(SP)联合阿奇霉素(AZ)(SPAZ)有用于孕期疟疾间歇性预防治疗(IPTp)的潜力,但其使用可能会增加与严重儿科感染相关的抗生素耐药菌的传播。在巴布亚新几内亚一项随机对照试验中,我们评估了854名参与试验的女性每月接受SPAZ-IPTp与单疗程SP联合氯喹(SPCQ)相比,对分娩时肺炎链球菌、流感嗜血杆菌和金黄色葡萄球菌的产妇鼻咽部携带情况及抗生素敏感性的影响。进行了血清分型,并通过纸片扩散法和Etest评估抗生素敏感性。检查了携带的潜在风险因素。接受SPAZ-IPTp的女性分娩时肺炎链球菌(SPAZ组为7.2%[30/418],SPCQ组为19.3%[84/436];P<0.001)和流感嗜血杆菌(分别为2.9%[12/418]和6.0%[26/436],P=0.028)的鼻咽部携带率显著降低,但金黄色葡萄球菌未降低。大环内酯类耐药肺炎球菌分离株数量较少,但在SPAZ组有所增加(13.3%[4/30],SPCQ组为2.2%[2/91];P=0.033)。13价肺炎球菌结合疫苗覆盖血清型的分离株比例相似(SPAZ组为10.3%[3/29],SPCQ组为17.6%[16/91];P=0.352)。尽管大环内酯类耐药分离株很少见,但在接受SPAZ-IPTp的女性中更常检测到,尽管该组产妇肺炎链球菌和流感嗜血杆菌的携带率显著降低。关于SPAZ-IPTp的未来研究应评估大环内酯类耐药肺炎链球菌和其他病原菌在母婴中的携带和持续存在情况,并评估其传播的临床意义。